Oil above US$100 and rising freight costs are putting pressure on company budgets, which makes reliable earnings expansion and clear leadership plans more valuable than ever. Australian high growth stocks with strong internal confidence can turn that pressure into pricing power, market share gains or smarter cost control. This piece highlights three high conviction picks from our growth screener that align analyst optimism with management ambition.
The stocks covered below are just a sample, and the full High Growth High Conviction screen surfaces 24 more companies with equally compelling stories that are not covered here. If you want to identify and analyze those extra high-conviction ideas quickly, head straight to the High Growth High Conviction screener .
Emerald Resources (ASX:EMR)
Emerald Resources is a Perth based gold producer whose High Growth High Conviction appeal comes from the 100% owned Okvau Gold Project in Cambodia, which drives about A$602 million from mine operations on roughly A$612 million of revenue, and underpins a market value of about A$4.3b.
Emerald Resources connects tightly to the High Growth High Conviction theme, with the Okvau Gold Mine associated with a 196.3% year on year lift in earnings and revenue of about A$612 million in 2026. Strong margins and high forecast ROE are noted as key factors in its compounding profile, subject to how one unseen pressure shapes future capital returns.
That unseen pressure is exactly what sits behind the Emerald Resources financial health report , where Emerald Resources' balance sheet and funding runway story really starts to separate from the pack.
Mesoblast (ASX:MSB)
Mesoblast is a Melbourne based biotech focused on regenerative medicine, using mesenchymal lineage cell therapies as its main growth engine within the High Growth High Conviction theme. It has generated about US$120 million from its allogeneic cellular medicines platform and carries a market value near A$2.5b.
For Mesoblast, the High Growth High Conviction appeal comes from its late stage cell therapy programs, where management is clearly building around a few high stakes assets rather than a broad product catalogue.
"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption. This would be most visible in revenue growth and operating leverage."
What happens to Mesoblast's margins and funding options depends heavily on how one future inflection in real world treatment demand plays out.
That turning point is exactly where the full narrative for Mesoblast shows how regulatory decisions, capital needs, and potential treatment uptake could be decoupling from what the headline story implies.
Pinnacle Investment Management Group (ASX:PNI)
Pinnacle Investment Management Group helps boutique fund managers take high conviction strategies to a wider audience, earning A$110 million from funds management operations in Australia and carrying a market value of about A$3.2b.
Pinnacle Investment Management Group matters for this High Growth High Conviction screen because it does not just run its own strategies. It builds the plumbing that lets high conviction affiliates reach more clients when conditions line up.
"Expansion of international affiliates and clients, with about one third of A$229.4 billion of affiliate FUM now sourced outside Australia and A$75 billion coming from more than 50 countries, can deepen diversification and support a larger revenue base as offshore fee streams build."
What happens next for Pinnacle will likely hinge on how one pressure point shapes the balance between steady fee income and more volatile performance driven earnings.
That balance is exactly what the full narrative for Pinnacle Investment Management Group unpacks in detail, showing how fee flows, affiliate growth and performance swings could be quietly reshaping Pinnacle's earnings mix.
Seeking Alternatives Before The Crowd?
Fresh ideas move first. Breakout momentum, currently flying under the radar, often gets noticed only after headlines appear. Scan these curated shortlists while it matters and consider your options early.
-
Target potentially sturdier paychecks from markets that move around you by reviewing the 6 dividend fortresses before yields change and crowd attention tightens.
-
Look for potential breakout miners and producers with leverage to metals demand by assessing the 16 top copper producer stocks while interest is still building rather than fully developed.
-
Track future-facing infrastructure players involved in grid upgrades by scanning the 43 power grid technology and infrastructure stocks while they remain relatively less followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
